Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Metformin has been widely used as an antidiabetic drug, and reported to inhibit cell proliferation in many cancers including non-small cell lung cancer (NSCLC). In NSCLC cells, metformin suppresses PI3K/AKT/mTOR signaling pathway, but effect of metformin on RAS/ RAF/MEK/ERK signaling pathway is controversial; several studies showed the inhibition of ERK activity, while others demonstrated the activation of ERK in response to metformin exposure. Metformin-induced activation of ERK is therapeutically important, since metformin could enhance cell proliferation through RAS/RAF/MEK/ERK pathway and lead to impairment of its anticancer activity suppressing PI3K/AKT/mTOR pathway, requiring blockade of both signaling pathways for more efficient antitumor effect. The present study tested the combination therapy of metformin and trametinib by monitoring the alterations of regulatory effector proteins of cell signaling pathways and the effect of the combination on cell viability in NCI-H2087 NSCLC cells with NRAS and BRAF mutations. We show that metformin alone blocks PI3K/AKT/mTOR signaling pathway but induces the activation and phosphorylation of ERK. The combination therapy synergistically decreased cell viability in treatment with low doses of two drugs, while it gave antagonistic effect with high doses. These findings suggest that the efficacy of metformin and trametinib combination therapy may depend on the alteration of ERK activity induced by metformin and specific celular context of cancer cells.
Abstract
Metformin has been widely used as an antidiabetic drug, and reported to inhibit cell proliferation in many cancers including non-small cell lung cancer (NSCLC). In NSCLC cells, metformin suppresses PI3K/AKT/mTOR signaling pathway, but effect of metformin on RAS/ RAF/MEK/ERK signaling pathway is controversial; several studies showed the inhibition of ERK activity, while others demonstrated the activation of ERK in response to metformin exposure. Metformin-induced activation of ERK is therapeutically important, since metformin could enhance cell proliferation through RAS/RAF/MEK/ERK pathway and lead to impairment of its anticancer activity suppressing PI3K/AKT/mTOR pathway, requiring blockade of both signaling pathways for more efficient antitumor effect. The present study tested the combination therapy of metformin and trametinib by monitoring the alterations of regulatory effector proteins of cell signaling pathways and the effect of the combination on cell viability in NCI-H2087 NSCLC cells with NRAS and BRAF mutations. We show that metformin alone blocks PI3K/AKT/mTOR signaling pathway but induces the activation and phosphorylation of ERK. The combination therapy synergistically decreased cell viability in treatment with low doses of two drugs, while it gave antagonistic effect with high doses. These findings suggest that the efficacy of metformin and trametinib combination therapy may depend on the alteration of ERK activity induced by metformin and specific celular context of cancer cells.
참고문헌 (29)
- Ashinuma H, "Antiproliferative action of metformin in human lung cancer cell lines", Oncol Rep, 28, pp.8~14 (2012)
- Chan BA, "Targeted therapy for non-small cell lung cancer : Current standards and the promise of the future", Transl Lung Cancer Res, 4, pp.36~54 (2015)
- Chou TC, "Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors", Eur J Biochem, 115, pp.207~216 (1981)
- Collisson EA, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
- Corte CMD, "Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cells", Oncotarget, 7, pp.4265~4278 (2016)
- De Luca A, "The RAS", RAF, ERK and the PI3K, pp.AKT signalling pathways : Role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin Ther Targets[DOI]
- Ding L, "Somatic mutations affect key pathways in lung adenocarcinoma", Nature, 455, pp.1069~1075 (2008)
- Do MT, "Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of RAF-ERK-Nrf2 signaling and AMPK-independent pathways", Toxicol Appl Pharmacol, 271, pp.229~238 (2013)
- Evans JMM, "Metformin and reduced risk of cancer in diabetic patients", BMJ, 330, pp.1304~1305 (2005)
- Govindan R, "Genomic landscape of non-small cell lung cancer in smokers and never-smokers", Cell, 150, pp.1121~1134 (2012)
- Griss T, "Metformin antagonizes cancer cell proliferation by suppressing mitochondrialdependent biosynthesis", Plos Biol, 13, pp.e1002309~ (2015)
- Hall GC, "Diabetes and the risk of lung cancer", Diabetes Care, 28, pp.590~594 (2005)
- Holderfield M, "Targeting RAF kinases for cancer therapy : BRAF mutated melanoma and beyond", Nat Rev Cancer, 14, pp.455~467 (2014)
- Taewan Kim, "Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells", 발생과 생식, 22(2), pp.133~142 (2018), 한국발생생물학회
- 고기현, "Synergistic Enhancement of Paclitaxel-Induced Inhibition of Cell Growth by Metformin in Melanoma Cells", 발생과 생식, 23(2), pp.119~128 (2019), 한국발생생물학회
- Ko JC, "Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells", Basic Clin Pharmacol Toxicol, 113, pp.56~65 (2013)
- Lai SW, "Antidiabetes drugs correlate with decreased risk of lung cancer : A population-based observation in Taiwan", Clin Lung Cancer, 13, pp.143~148 (2012)
- Liu W, "Drug resistance to targeted therapeutic strategies in non-small cell lung cancer", Pharmacol Ther, 206, pp.107438~ (2020)
- Martin MJ, "Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A", Cancer Discov, 2, pp.344~355 (2012)
- Morgillo F, "Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines", Clin Cancer Res, 19, pp.3508~3519 (2013)
- Planchard D, "Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, pp.iv192~iv237 (2018)
- Sayed R, "Metformin addition to chemotherapy in stage IV non-small cell lung cancer : An open label randomized controlled study", Asian Pac J Cancer Prev, 16, pp.6621~6626 (2015)
- Schrank Z, "Current molecular-targeted therapies in NSCLC and their mechanism of resistance", Cancers, 10, pp.224~ (2018)
- Shaw RJ, "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin", Science, 310, pp.1642~1646 (2005)
- Stinchcombe TE, "Annual review of advances in lung cancer clinical research : A report for the year of 2009", J Thorac Oncol, 5, pp.935~939 (2010)
- Tseng SC, "Metformin-mediated downregulation of p38 mitogen-activated proteinkinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel", Biochem Pharmacol, 85, pp.583~594 (2013)
- Vancura A, "Metformin as an anticancer agent", Trends Pharmacol Sci, 39, pp.867~878 (2018)
- "WHO outlines steps to save 7 million lives from cancer" (2020)[URL]
- Yousef M, "Metformin in lung cancer : Review of in vitro and in vivo animal studies", Cancers, 9, pp.45~ (2017)